venlafaxine hydrochloride(redirected from Riva-Venlafaxine XR)
Pharmacologic class: Phenethylamine derivative
Therapeutic class: Antidepressant, anxiolytic
Pregnancy risk category C
Inhibits neuronal serotonin and norepinephrine reuptake and slightly inhibits dopamine reuptake
Capsules (extended-release): 37.5 mg, 75 mg, 150 mg
Tablets: 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg
Tablets (extended-release): 37.5 mg, 75 mg, 150 mg, 225 mg
Indications and dosages
Adults: In outpatients, 75 mg P.O. daily in two or three divided doses; may increase in increments of 75 mg/day q 4 or more days to a maximum of 225 mg/day; extended-release form can be given as a single daily dose. In hospitalized patients, 75 mg P.O. daily in two or three divided doses; may increase in increments of 75 mg/day q 4 days to a maximum of 375 mg/day given in three divided doses.
➣ Generalized anxiety disorder
Adults: Single dose of 37.5 to 75 mg (extended-release) P.O. daily; may increase in increments of 75 mg/day q 4 days to a maximum of 225 mg/day
➣ Panic disorder
Adults: 37.5 mg (extended-release) P.O. daily for 7 days; increase to 75 mg P.O. daily for 7 days; then increase by 75 mg daily at weekly intervals to a maximum of 225 mg P.O. daily
➣ Social anxiety disorder
Adults: 75 mg (extended-release capsule) P.O. daily as a single dose
• Hepatic or renal impairment
• Premenstrual dysphoric disorder
• Hypersensitivity to drug
• MAO inhibitor use within past 14 days
Use cautiously in:
• cardiovascular disease; hypertension; heart failure, recent myocardial infarction, and other conditions in which increased heart rate poses a danger; hepatic or renal impairment; glaucoma; hyperthyroidism; hyponatremia; syndrome of inappropriate antidiuretic hormone secretion (SIADH)
• history of seizures, neurologic impairment, or drug abuse
• pregnant or breastfeeding patients
• children younger than age 18.
Don't give within 14 days of MAO inhibitors.
CNS: abnormal dreams, anxiety, dizziness, headache, insomnia, nervousness, abnormal thinking, agitation, confusion, depersonalization, drowsiness, emotional lability, worsening depression, twitching, tremor, asthenia, paresthesia, mania, hypomania, suicidal ideation or behavior (especially in child or adolescent)
CV: chest pain, hypertension, palpitations, tachycardia, vasodilation
EENT: visual disturbances, blurred vision, mydriasis, tinnitus, rhinitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia
GU: urinary frequency or retention, sexual dysfunction, abnormal ejaculation, anorgasmia, erectile dysfunction
Metabolic: hyponatremia, SIADH
Skin: bruising, pruritus, rash, diaphoresis, photosensitivity
Other: altered taste, weight loss, chills, yawning
Drug-drug. Cimetidine: increased venlafaxine effects
MAO inhibitors: potentially fatal reactions
Sumatriptan, trazodone: serotonin syndrome (including altered level of consciousness)
Drug-diagnostic tests. Sodium: decreased level
Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression
S-adenosylmethionine (SAM-e), St. John's wort: increased risk of sedative or hypnotic effects
Monitor neurologic status, particularly for seizures, worsening depression, and suicidal ideation.
• Closely monitor vital signs and cardiovascular status. Stay alert for hypertension and tachycardia.
• Monitor nutritional status, hydration, and weight.
• Tell patient taking extended-release capsules to swallow them whole without chewing, breaking, dividing, or dissolving.
Caution patient not to stop therapy abruptly.
Advise patient to promptly report seizures, worsening depression, or suicidal thoughts (especially in child or adolescent).
• Caution patient to avoid driving and other dangerous activities until drug effects are known.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.